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Abstract
Background: Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic
disease with few treatment options other than renal replacement therapy. p21, a cyclin kinase
inhibitor which has pleiotropic effects on the cell cycle, in many cases acts to suppress cell cycle
progression and to prevent apoptosis. Because defects in cell cycle arrest and apoptosis of renal
tubular epithelial cells occur in PKD, and in light of earlier reports that polycystin-1 upregulates p21
and that the cyclin-dependent kinase inhibitor roscovitine arrests progression in a mouse model,
we asked whether (1) p21 deficiency might underlie ADPKD and (2) the mechanism of the salutary
roscovitine effect on PKD involves p21.
Methods: p21 levels in human and animal tissue samples as well as cell lines were examined by
immunoblotting and/or immunohistochemisty. Apoptosis was assessed by PARP cleavage. p21
expression was attenuated in a renal tubular epithelial cell line by antisense methods, and
proliferation in response to p21 attenuation and to roscovitine was assessed by the MTT assay.
Results: We show that p21 is decreased in human as well as a non-transgenic rat model of
ADPKD. In addition, hepatocyte growth factor, which induces transition from a cystic to a tubular
phenotype, increases p21 levels. Furthermore, attenuation of p21 results in augmentation of cell
cycle transit in vitro. Thus, levels of p21 are inversely correlated with renal tubular epithelial cell
proliferation. Roscovitine, which has been shown to arrest progression in a murine model of PKD,
increases p21 levels and decreases renal tubular epithelial cell proliferation, with no affect on
apoptosis.
Conclusion: The novelty of our study is the demonstration in vivo in humans and rat models of a
decrement of p21 in cystic kidneys as compared to non-cystic kidneys. Validation of a potential
pathogenetic model of increased cyst formation due to enhanced epithelial proliferation and
apoptosis mediated by p21 suggests a mechanism for the salutary effect of roscovitine in ADPKD
and supports further investigation of p21 as a target for future therapy.
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Background
Autosomal dominant polycystic kidney disease (ADPKD)
is a common genetic disorder and, due to the absence of
any currently available effective treatment, the most com-
mon genetic cause of end-stage renal disease (ESRD).
While the pathogenesis of ADPKD is often viewed in light
of defects in trans-epithelial fluid transport and associated
channels causing massive and abundant cyst formation, it
is becoming increasingly clear that ADPKD is also a dis-
ease of disordered epithelial cell cycle regulation and
apoptosis. In addition, due to its monoclonality in rela-
tion to proliferating renal tubular epithelial (RTE) cells,
ADPKD has been described as "a neoplasm in disguise"
[1]. In kidneys from ADPKD patients, cystic epithelial
cells have a markedly high mitotic rate as measured by a
variety of proliferative markers, and an increased level of
apoptosis[2], findings which may be due to the failure of
appropriate cell cycle inhibition. Thus, a somewhat sim-
plistic view of ADPKD, from a cell cycle perspective, is one
of increasing tubular epithelial proliferation and failure of
normal apoptotic inhibition.
The cyclin-dependent kinase inhibitors (CKI) function in
mitogenic signaling through their interaction with the
cyclins and the cyclin dependent kinases [3], and through
proliferating cell nuclear antigen (PCNA) [4]. The CKIs
influence apoptosis through interaction with a variety of
second messengers [5], and the CKI p21 specifically has
been shown to possess pleiotropic effects on cell division
and apoptosis in a variety of cell systems, such that the net
result of p21 activation is variable and dependent on cell
type, as well as on its subcellular localization [5-8]. Due to
the pivotal role of epithelial cell cycle regulation in the
generation of PKD cysts, and in light of the similarities of
PKD to neoplasia, examination of p21 is a logical poten-
tial target for novel therapeutic approaches in this disease.
Germino et al[9] were the first to suggest a relationship
between p21 and PKD by showing that p21 is induced by
the product of the Pkd1 gene, polycystin-1. While these
investigators also showed that p21 levels were reduced in
Pkd1 knockout mice, there has to our knowledge been no
published study examining the function of p21 in human
tissues or in non-knockout animal models of this disease.
In this study, we examine the expression of p21 in human
tissue as well as in rat tissues. Very recent data has sup-
ported the role of cyclin kinase inhibition as possible
treatment of PKD, using the specific inhibitor roscovi-
tine[10].
We now show that p21 is consistently downregulated in
all models examined. Furthermore, in the commonly
used Han:SPRD rat model, where the mutation is in the
Pkdr1 gene [11], there appears to be a male gender-specific
predilection for p21 attenuation, which is consistent with
observed gender dimorphism of disease severity in clini-
cal and experimental studies [12,13]. We have also begun
to evaluate whether p21 is pathogenic in ADPKD, by
showing that hepatocyte growth factor (HGF), which
induces transition from a cystic to a tubular phenotype in
vitro, increases p21 levels, and that levels of p21 correlate
inversely with proliferation of RTE cells. Finally, we show
that not only does roscovitine decrease proliferation of
RTE cells, but it also increases p21 and consequently does
not cause increased apoptosis at low doses, suggesting a
mechanism for its salutary effect in this disease.
Methods
Experimental models
Han:SPRD rats: These studies were conducted in
Han:SPRD rats, from a colony propagated from breeding
pairs kindly provided by Dr. Benjamin D. Cowley, Jr.
(then at the University of Kansas Medical Center, Kansas
City, KS). Male and female heterozygous cystic rats (Cy/+)
and unaffected littermate control rats (+/+) were raised to
12 weeks of age. After anesthesia with Inactin (100 mg/kg
i.p.), kidneys were removed and frozen at -80° for protein
expression studies, and put into 10% formalin for immu-
nohistochemistry (IHC) studies as below. The Portland
Veterans Affairs Institutional Animal Care and Use Sub-
committee approved these studies.
Human ADPKD: End stage kidneys from 11 male patients
with ADPKD and kidney samples from 5 male patients
without ADPKD (without fibrosis) were obtained at surgi-
cal nephrectomy via institutional review board (IRB)-
approved protocols (OHSU IRB 6044VAW; PVAMC IRB
00349). After nephrectomy, ADPKD kidneys were stored
on ice during transport. For IHC, tissue was fixed in 10%
formalin and processed for paraffin blocks for storage
until section at 5 µm.
Immunoblotting
The Han:SPRD Rat and human kidneys were homoge-
nized in solubilization buffer (50 mM TRIS, 150 mM
NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1.0% Tri-
ton-X 100, and protease inhibitors [leupeptin, 20 µg/ml;
benzamidine, 20 µg/ml; phenyl methylsulfonyl fluoride
[PMSF], 40 µg/ml)]). These homogenates were centri-
fuged at 12,000 × g for 30 min at 4°C and supernatants
were collected. Total protein content was determined by
BCA analysis (Pierce Chemical Co., Rockford, IL).
Denatured proteins were separated through a 12% SDS-
polyacrylamide gel and transferred to PVDF membranes
(Bio-Rad Laboratories, Hercules, CA). Membranes were
washed and blocked overnight with TRIS buffered saline
0.05% Tween-20 (TBS-T), containing 5% nonfat dry milk.
Following blocking, membranes were again washed (TBS-
T), and incubated overnight with a rabbit polyclonal anti-BMC Nephrology 2007, 8:12 http://www.biomedcentral.com/1471-2369/8/12
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human p-21 (H-164; Santa Cruz Biotechnology Inc.,
Santa Cruz, CA), diluted 1:3000 in TBS-T. Immunodetec-
tion was accomplished by incubating membranes with a
goat anti-rabbit-IgG secondary antibodies conjugated
with horseradish peroxidase (HRP) for 45 minutes
(Pierce, 1:100,000) in TBS-T containing 5% nonfat dry
milk. Visualization was performed with enhanced chemi-
luminiscence (ECL) western-blotting kit (Supersignal
West Dura, Pierce) according to the manufacturer's
instructions. The membranes were then stripped, re-
blocked, and re-incubated for 1 hr at room temperature
with goat Actin antibody (I-19; Santa Cruz), 1:4000, fol-
lowed by 45-min incubation with anti-goat-IgG second-
ary antibody conjugated with HRP (1:40,000, Santa
Cruz), and reaction with ECL. Resultant films (Eastman
Kodak Co., Scientific Imaging Systems, New Haven, CT)
were scanned using a flatbed scanner and image analysis
was performed with the ImageJ gel analysis algorithm.
Immunohistochemistry
The same antisera as described above were used for immu-
nohistochemical detection of rat or human p21. Sections
were deparaffinized in xylene, rehydrated through graded
ethanols to water, and pretreated by steaming in 10%
CITRA buffer (BioGenex Laboratories, San Ramon, CA).
After being treated with protein-blocking solution, the
slides were incubated overnight at 4°C with primary anti-
body (diluted 1:500) or with the same concentration of
nonimmune IgG as a control. Endogenous peroxidase
activity was blocked with 3% H2O2 solution in methanol.
The primary antibody was localized using the Vectastain
ABC-Elite peroxidase detection system (Vector Laborato-
ries, Burlingame, CA). This was followed by reaction with
diaminobenzidine as chromogen and counterstaining
with hematoxylin (Sigma). Sections of each polycystic
kidney were processed in parallel with appropriate control
tissue. Visualization occurred with a Zeiss Axioskop
microscope connected to a Micropublisher 3.3 digital
camera (QImaging; Burnaby, B.C., Canada) interfaced
with a Macintosh G5 computer (Apple, Cupertino, CA)
utilizing QCapture software (QImaging).
Digital image processing
After data acquisition, raw images were opened with Pho-
toshop 7.0 for Macintosh (Adobe; San Jose; CA) and
images were processed with the built-in adjustments func-
tion of "auto levels," "auto contrast," and "auto color." No
further image manipulation occurred.
Cell culture and antisense transfections
MDCK (Madin-Darby canine kidney) cells were obtained
from Dr. John Payne at UC Davis. The cells were main-
tained in Dulbecco's media and 10% FBS and 1% Penicil-
lin/Streptomycin.
The canine p21 antisense oligodeoxynucleotide (ODN;
sequence 5'-GTC-AAA-GTT-CCA-TCG-CTC-CC-3') was
synthesized by Molecula (Stering, VA). Control ODN (5'-
GGA-CTA-CTA-CAC-TAG-ACT-AC-3', designed and tested
by the vendor) was synthesized by Biognostik (Germany).
For the transfection procedure, 1 × 105 cells were seeded
in 6 well plates 24 hr before transfection and cells were
washed with sterile PBS before the transfection. The trans-
fection reagent, GeneJuice (Novagen, Germany) was
diluted with OptiMEM first and then the ODNs were
added in diluted GeneJuice mixture. The ODN mixture
was added to the cells for 24 hr.
MTT assay
MDCK cells were seeded in 96 well plate 24 h before treat-
ment with ODN or roscovitine (Sigma). For ODN trans-
fection, 200 nM and 400 nM antisense or control ODN
were added into the cells and incubated for 24 h. For ros-
covitine treatment, 1–10 ug/ml roscovitine was added in
serum-containing media and incubated for 24 h. Media
containing ODNs or roscovitine was removed and cells
were incubated with 50 µg/ml MTT (Sigma) for 4 h at
37°C. Purple formazan was solubilized and samples were
measured by multiwell scanning spectrophotometer at
570 nm.
Statistical analysis
Values are reported as means ± SEM. Statistical analysis
was performed by unpaired t test, or by analysis of vari-
ance followed by computation of modified t  values
according to the method of Bonferroni (for multiple
groups), as appropriate. Statistical significance was
defined as p < 0.05. Values are means ± SEM.
Results
p21 is decreased in ADPKD patients and in rat models of 
PKD
While p21 has been shown to be induced by polycystin-
1[9], there are as yet no studies demonstrating that a lack
of p21, as would be expected with mutant PKD1, occurs in
vivo in humans or in those animal models not character-
ized by targeted gene disruption. We tested the hypothesis
that p21 is downregulated in human ADPKD tissues, and
then further tested generalizability of the findings in a rat
non-knockout model. By immunoblotting, renal expres-
sion of p21 was significantly attenuated in cystic kidneys
from human ADPKD patients, as compared with kidneys
from noncystic control patients (Fig. 1; p < 0.05). By
immunohistochemical analysis, there was intense p21
staining in normal kidneys. This staining was most pro-
nounced in the renal tubules, with relatively sparse stain-
ing in glomeruli. In the cystic kidneys, staining was
essentially absent in all kidney segments (Fig. 2, right pan-
els), similar to slides incubated with non-immune serumBMC Nephrology 2007, 8:12 http://www.biomedcentral.com/1471-2369/8/12
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(incubation with a normal rabbit IgG primary antibody;
NI in Fig. 2).
There exist several animal models of ADPKD, each with its
distinct advantages and disadvantages. Of the available
rodent models, the Han:SPRD rat is commonly used, and
may be the only rodent model which progresses to ESRD.
We evaluated control and cystic kidneys from male
Han:SPRD rats, and then sought to determine whether the
observed changes were replicated in female rats. General
characteristics of the Han:SPRD rats used are depicted in
Table 1. Females were smaller than males, but the cystic
phenotype did not affect body weight. The kidney and
kidney:body weight ratios were markedly increased in
cystic males, as compared with noncystic controls
(p < 0.01). In cystic females, renal enlargement was also
present, but to a significantly lesser magnitude than was
seen in cystic males (p < 0.01). These results are consistent
with prior observations of gender dimorphism with
respect to progression of cystic disease in this model
[13,14].
Expression of p21 in cortical homogenates from control
and cystic Han:SPRD animals was assessed by immunob-
lotting (Fig. 3). Renal expression of p21 was significantly
attenuated in cystic male rats, as compared with noncystic
controls (p < 0.01). In contrast, renal p21 expression in
cystic females did not differ from that seen in noncystic
control females. Immunohistochemical expression stud-
ies mirrored the findings from immunoblotting. In non-
cystic control male rats, p21 staining was evident in the
glomeruli as well as the tubulointerstitial compartment
(Fig. 2, top left), which was somewhat different from the
human tissues which showed relatively sparse glomerular
staining. However, in cystic males, staining was much less
intense, particularly in the tubulointerstitial and cystic
compartments (Fig. 2, bottom left). Non-immune experi-
ments (incubation with a normal rabbit IgG primary anti-
body) yielded little or no signal (NI in Fig. 2).
HGF, which induces transition from a cystic to a tubular 
phenotype, induces p21
MDCK cells, a canine RTE cell line, have been utilized in
in vitro PKD studies for many years, and thus the cystic
behavior of these cells has been well characterized. MDCK
cells spontaneously form cysts when cultured in 3D colla-
gen gels and undergo in vitro tubulogenesis when treated
with HGF; thus HGF functions as a "molecular switch"
from cyst to tubule formation [15]. Interestingly, while
not evaluated in relation to a cystic phenotype, p21 has
been shown to be induced by HGF in several cell lines
[16], consistent with our hypothesis that p21 mediates the
tubulogenic, not the cystic, phenotype. Thus, these cells
are ideal for examining the role of p21 on cyst formation.
MDCK cells were serum-starved in order to synchronize
them in Go phase and were subsequently incubated with
recombinant human HGF at 20 and 40 ng/ml for 24 h,
and immunoblotted with p21 antibody. HGF stimulation
of these cells at 20 and 40 ng/ml resulted in the induction
of p21 for 24 hours (Fig. 4a). Due to the doublet observed
with this antibody in MDCK cell lysate, we utilized anti-
gen competition in order to determine that the lower
molecular weight band represents p21 (Fig. 4b). Thus,
p21 is downstream of HGF and may mediate its function
in maintaining the tubular (and hence non-cystic) pheno-
type [15], such that its absence contributes to cyst forma-
tion. While this data is consistent with our finding that
p21 is decreased in cystic tissue, whether HGF lies within
the polycystin 1 → p21 pathway remains under active
investigation in our laboratories.
p21 is decreased in kidneys from ADPKD patients Figure 1
p21 is decreased in kidneys from ADPKD patients. [top] Kid-
ney protein extracts from control (closed) and PKD (open) 
human males were immunoblotted with an anti-p21 and β-
actin antibody. Immunoblots were analyzed by densitometry 
with ImageJ as described in Methods. [bottom] p21 expres-
sion is presented as the ratio of intensity of p21 bands com-
pared to intensity of actin bands presented as mean ± SEM. * 
p < 0.01 versus within gender control. Values within each bar 
denote the number of kidneys utilized.BMC Nephrology 2007, 8:12 http://www.biomedcentral.com/1471-2369/8/12
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Attenuation of p21 results in increased tubular epithelial 
cell proliferation
One of the functions of p21 is to arrest cell proliferation
by virtue of its association with PCNA (thereby eliminat-
ing the action of PCNA on transcription) and/or by its
inhibition of cyclin/cdk association [4,17,18]. However, it
is now clear that this property of p21 is cell-type depend-
ent, since p21 can also, under some contexts, function as
a cyclinD/cdk4 assembly factor [19,20] and has variable
effects on apoptosis [5,21,22]. We next asked whether
attenuation of p21 in MDCK cells, which have the poten-
tial to form either cysts or tubules [23], results in
enhanced cell cycle transit. In the context of its putative
role in PKD as an inhibitor of cystogenesis, p21 would be
expected to decrease RTE cell proliferation and thus pre-
vent cyst formation.
We utilized an antisense ODN approach, which we have
previously found to be successful in both human[21] and
rat [20] cell lines. We have previously shown that a 21-
mer antisense ODN to human p21 has a nearly 100%
transfection efficiency in human cells [20]. We designed a
20-mer phosphorothioated antisense ODN using the
canine p21 sequence and demonstrated that this con-
struct, when transiently transfected into MDCK cells at
both 400 and 600 nM, results in attenuation of p21 when
Table 1: General characteristics of Han:SPRD rats (12 weeks old)
Males Females
Control Cystic Control Cystic
(n = 9) (n = 12) (n = 7) (n = 11)
Body wt (gms) 385 ± 8 356 ± 7 253 ± 4† 242 ± 4†
LKW (gms) 1.47 ± 0.05 4.19 ± 0.13* 0.86 ± 0.03† 1.89 ± 0.04*†
LKW/100 gms BW 0.38 ± 0.01 1.18 ± 0.03* 0.34 ± 0.01 0.76 ± 0.01*†
Values are means ± SEM. LKW, left kidney weight; BW, body weight. * p < 0.01 vs. respective noncystic control; † p < 0.01, female vs. respective 
male group
Representative immunohistochemical expression of p21 in male cystic and noncystic Han:SPRD rats (left), and male PKD and  control humans (right) Figure 2
Representative immunohistochemical expression of p21 in male cystic and noncystic Han:SPRD rats (left), and male PKD and 
control humans (right). Upper panels show p21 localization from control sections, and the lower panels show cystic sections. 
Also shown are sections (NI) pre-incubated with non-immune serum that demonstrate antibody specificity. In sections from 
control male kidneys, p21 was widely distributed, whereas in sections from cystic male kidneys, p21 was only sparsely 
detected.BMC Nephrology 2007, 8:12 http://www.biomedcentral.com/1471-2369/8/12
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compared to an equivalent concentration of scrambled
control ODN (Fig. 5a). Specificity of the canine ODN was
demonstrated by its lack of effect on actin protein levels.
Cell cycle progression of p21-attenuated MDCK cells was
assessed by the MTT proliferation assay. Antisense p21
ODN transfection of MDCK cells at 400 and 600 nM
showed increased cell proliferation as compared to cells
transfected with scrambled control ODN (Fig. 5b). The
increase in p21 with scrambled control ODN was likely a
result of non-specific cellular stress and 600 nM ODNs are
more toxic to cells than 400 nM, showing the overall
lower proliferation rate; however, the levels of p21 (Fig.
5a) correspond inversely with cell proliferation (Fig. 5b),
consistent with the established cell cycle inhibitory effect
of p21, and supporting our hypothesis that decreased p21
as seen in PKD is associated with increased RTE prolifera-
tion. Thus, p21 is playing a growth suppressive role in RTE
cells, such that the lower levels of p21 observed in cystic
tissue is likely resulting in increased cell cycle transit and
contributing to cyst formation.
Roscovitine decreases cell proliferation in parallel with 
p21 augmentation
The potent CDK inhibitor roscovitine has been recently
shown to arrest PKD in a mouse model[10]. We asked
whether the MDCK model of PKD that we have employed
in this study responds as expected to this inhibitor. When
incubated with a range of roscovitine concentrations, pro-
HGF increases p21 in MDCK cells Figure 4
HGF increases p21 in MDCK cells. a. MDCK cells were 
seeded and serum starved for 24 h. HGF (20 and 40 ng/ml) 
was added for 24 h in serum-free quiescence media and the 
cells were lysed and immunoblotted with anti-p21 and β-
actin antibodies. Human p21 was used for p21 positive con-
trol and indicates that lower band of doublet is p21. QM: qui-
escence media; p21 pos: p21 positive control (HeLa cell 
lysate). Densitometry is shown; *p < 0.05 as compared to 
QM alone. Experiment shown is representative of two 
experiments. b. In order to determine which band of the 
doublet represents p21, MDCK and HeLa control cell lysate 
were immunoblotted with p21 antibody alone or with p21 
antibody which had been pre-incubated with GST- tagged 
p21 antigen, demonstrating that the lower molecular weight 
band is p21.
p21 is decreased in kidneys from male Han:SPRD rats Figure 3
p21 is decreased in kidneys from male Han:SPRD rats. [top] 
Protein extracts in kidney cortical preparations from control 
(closed) and cystic (open) male and female Han:SPRD rats 
were immunoblotted with an anti-p21 and β-actin antibodies. 
Immunoblots were analyzed by densitometry with ImageJ as 
described in Methods. [bottom] p21 expression is presented 
as the ratio of intensity of p21 bands compared to intensity 
of actin bands presented as mean ± SEM. * p < 0.01 versus 
control of same gender. Values within each bar denote the 
number of animals utilized.BMC Nephrology 2007, 8:12 http://www.biomedcentral.com/1471-2369/8/12
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liferation of MDCK cells, as measured by the MTT assay,
showed a dose dependent decrease, reaching significance
at all concentrations (Fig. 6).
Consistent with our model of p21 decrease being associ-
ated with the cystic phenotype, we found that p21 was
induced in a dose dependent fashion by roscovitine (Fig.
7), suggesting a mechanism for the roscovitine effect prox-
imal to cyclin-cdk inhibition. Since PKD is associated with
increase RTE apoptosis[2] and p21 possesses an anti-
apoptotic function in several cell lines [5,21], we would
expect potential drug therapies for PKD to not be associ-
ated with programmed cell death, in contrast to what
would be expected in the cancer chemotherapy setting
[24]. Thus, while we have in fact observed apoptosis at
higher concentrations of roscovitine associated with
decreased p21, consistent with its chemotherapeutic util-
ity (data not shown), there was no increase in apoptosis,
as measured by the absence of a PARP cleavage (lower
molecular weight) band, in cells incubated with this p21-
augmenting lower concentration of roscovitine (Fig. 7). In
addition, the lack of apoptosis seen here supports the like-
lihood that the MTT assay reflects a decrease in cell prolif-
eration rather than an increase in apoptosis.
Discussion
ADPKD is one of the most common genetic diseases and
is the most common hereditary renal disease in the US,
accounting for 4.7% of ESRD population, and for which
the cost of medical care exceeds $200 million per year.
While no specific therapies currently exist for this disease,
recent research into the pathogenesis of cyst formation,
utilizing both animal models of the disease as well as cell
culture systems which form cysts, has revealed pathways
which will ultimately lead to the development of novel
therapeutic approaches. One of these pathways involves
key arbiters of cell cycle progression and apoptosis, the
cyclins, their associated kinases, and the cyclin kinase
inhibitors, of which group p21 is a member. The concept
of targeting the cyclin pathway for PKD therapy has been
reinforced recently with the publication of a study in a
murine PKD model (jck mice) showing that the cancer
chemotherapeutic agent and CDK inhibitor, roscovitine,
has long-term beneficial effects on disease progression
[10]. In fact, this study is consistent with the concept of
Roscovitine decreases proliferation and increases p21 with  no effect on apoptosis Figure 6
Roscovitine decreases proliferation and increases p21 with 
no effect on apoptosis. MDCK cells were seeded 24 h before 
treatment. Roscovitine (at the concentrations indicated) was 
added to the cells for 24 h and then the cells were harvested 
and subjected to the MTT assay as described in Materials and 
Methods. QM is serum-free media; * p < 0.05 compared to 
serum alone. Experiment shown is representative of at least 
three experiments.
Levels of p21 are inversely proportional to MDCK cell prolif- eration Figure 5
Levels of p21 are inversely proportional to MDCK cell prolif-
eration. a. MDCK cells were seeded 24 h before transfec-
tion, and transfected with antisense p21 (AS) or scrambled 
sequence control (SC) ODN in serum-reduced medium as 
described in Methods. Cell lysates were immunoblotted with 
anti-p21 and β-actin antibodies. GJ: Gene-Juice (transfection 
reagent); opti: Optimem medium. b. MDCK cells transfected 
with antisense p21 or control ODNs were incubated with 
MTT and purple soluble formazan was assessed as described 
in Methods. Experiments shown are representative of at least 
two experiments.BMC Nephrology 2007, 8:12 http://www.biomedcentral.com/1471-2369/8/12
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cyst formation in ADPKD being a monoclonal prolifera-
tion of polycystin-deficient RTEs, the disease having simi-
larities to neoplasia [1]. In addition, the observed
increased rate of renal tissue apoptosis in PKD[2] further
supports the investigation of cancer-relevant signaling
proteins as potential targets for this disease.
While the cystic epithelium in ADPKD has well described
derangements in ion transporters (such as the Na+/K+-
ATPase), ADPKD is also a disease of both hyperactive RTE
proliferation and increased apoptosis. Research into
molecular pathways involved in cystogenesis has mark-
edly accelerated since the elucidation of the genetic
defects which accompany ADPKD. In particular, those sig-
naling events which lead to increased proliferation of
cystic epithelium are now being dissected out in several
laboratories. In this study, we have built on the observa-
tion that polycystin-1, the gene product of PKD1 which is
mutated in 85% of ADPKD cases, induces the cyclin
kinase inhibitor p21[9]. We have shown for the first time
that this paradigm holds up in humans as well as in an
established rat model of this disease. In addition, our data
is consistent with the known anti-apoptotic function of
p21 elucidated in our and others' laboratories [5,21,25],
since ADPKD is known to be associated with increased
apoptotic loss of renal tissue[2], a finding which would be
expected to occur in the presence of the reduced levels of
p21 which we observed in this study.
The cyclin-dependent kinases (CDKs) are a well-con-
served family of serine/threonine protein kinases (one in
yeast and at least 8 in animals) which function in
mitogenic signaling through their activation by the cyc-
lins. This in turn leads to a cascade of events whereby the
mitogen-stimulated, cyclin D-dependent kinases phos-
phorylate retinoblastoma (Rb) protein, causing release of
phosphorylated Rb from the transcription factor family
known as E2F, and allowing S-phase specific gene tran-
scription and subsequent progression through the G1/S
transition. Cell cycle progression in normal, non-trans-
formed (e.g. epithelial) cells is finely regulated by the
interplay between the cdks and the CKIs (such as p21 and
p27), as well as their concentrations at different points of
the cell cycle (reviewed in [3,26]).
We have previously shown that attenuation of p21 is anti-
hypertrophic in renal mesangial cells in models of dia-
betic nephropathy[27], and plays an assembly factor role
in vascular smooth muscle cells [20], but the function of
this protein in RTEs has not been well investigated. Our
present findings that ADPKD, which is characterized by
increased RTE cell growth, may in fact be a disease which
results from diminished p21 expression in affected tissues
are consistent with recent data showing that polycystin-1
induces p21 [9] and causes resistance to apoptosis [23].
Our data is supported by another study demonstrating
that immortalized proliferation of mouse embryonic
fibroblasts from PKD1(-/-) mice occurs without the induc-
tion of p53 and (at late passage) p21 [28], as well a study
showing that the CDK inhibitor roscovitine arrests disease
progression[10].
There is a clear gender dimorphism with respect to pro-
gression in patients with ADPKD, with male patients pro-
gressing at a more rapid rate than female patients [13,14].
Consistent with this finding, our data indicate reduced
expression of p21 in cystic kidneys from male, but not
female, Han:SPRD rats. Estrogen has been shown to
upregulate p21 in vitro[29], and may have contributed to
the higher p21 levels in the cystic female rats in the
present study. These observations are consistent with the
hypothesis that suppression of p21 may play at least a per-
missive role in cystogenesis
p21 has been shown to have both assembly factor [19,20]
and CDK inhibitory [4,17,18] functions, depending on
the cell type examined. Thus, it was not clear at the outset
that p21 would be cell cycle inhibitory or permissive in
RTEs. Using an assay of S-phase cell cycle transit in a
canine RTE cell line, we confirmed that the role of p21 in
RTE cells is growth-suppressive. This data is supportive of
our contention that the absence or diminution of p21 in
cysts from PKD animal models may be pathogenic for cyst
formation.
Roscovitine increases p21 with no effect on apoptosis Figure 7
Roscovitine increases p21 with no effect on apoptosis. 
MDCK cells were seeded 24 h before treatment. Roscovitine 
(at the concentrations indicated) was added to the cells for 
24 h and then the cells were harvested and subjected immu-
noblotted with p21, β-actin, and PARP antibodies. PARP con-
trol (+PARP) represents cells treated with the DNA 
damaging agent doxorubicin showing the lower molecular 
weight cleavage band. QM is serum-free media; ser is serum-
containing media.BMC Nephrology 2007, 8:12 http://www.biomedcentral.com/1471-2369/8/12
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Roscovitine is a potent inhibitor of several cyclin-cdk pairs
and is in clinical trials as an anti-cancer agent. Due to the
similarity of PKD with neoplasia given the monoclonal
origins of this disease, the recent demonstration of its
long-lasting beneficial effect in a murine PKD model [10]
was not unexpected. While investigation in non-cancer
cell lines has not to our knowledge been reported, other
investigators have shown a small decrease in p21 levels in
vitro in prostate tumor spheroids [30]. Our finding of a
dose-dependent increase in p21 with roscovitine in RTEs
in the absence of increased apoptosis is consistent with
our scheme for the function of p21 in PKD in these cells
(Fig. 8), and, furthermore, suggests a mechanism for this
newly identified therapeutic.
The mammalian target of rapamycin (mTOR) inhibitors,
such as rapamycin, are now being recognized as having
salutary effects in cyst formation and disease progression
in human and animal models of ADPKD [31-33]. These
compounds have recently been shown to be of benefit in
kidney cancer [34], a disease with similarities to PKD, and
p21 serves as a prognostic marker in renal cell carcinoma
[35]. Furthermore RAD001, a rapamycin analog, has been
shown to sensitize tumor cells to apoptosis through inhi-
bition of p21 translation [36], which is consistent with
this CKI being a potential target in a variety of malignan-
cies [26] as well as in diabetic renal hypertrophy [27,37].
However, our finding that p21 is decreased in ADPKD,
while in agreement with earlier studies showing that
PKD1-deficient cells express lower p21, is not in complete
concordance with the mTOR inhibitor data. This discrep-
ancy may be explained by the pleiotropic effects of p21, as
well as the stage at which p21 is inhibited: it is possible
that a decrease in p21 levels in early stages of the disease
allows RTEs to grow and form cysts via its cyclin/cdk
inhibitor function, whereas mTOR inhibitors may be use-
ful in later stages of the disease to decrease p21 and
thereby attenuate cell growth via its assembly factor role
[20]. When p21 is phosphorylated by upstream molecules
such as phosphorylated Akt, p21 is translocated into the
cytosol to act as an anti-apoptotic protein. Therefore, a
decreased cytosolic p21 may result in inducing apoptosis
which is the same effect as caspase inhibition [38]. It is
also possible that, due to the global decrease in protein
translation by mTOR inhibitors, p21 attenuation is unre-
lated to the effect of these drugs in PKD.
To further examine the mechanism by which cyst forma-
tion occurs by means of p21 attenuation, we utilized the
growth factor HGF. MDCK cells spontaneously form cysts
when cultured in 3D collagen gels and undergo in vitro
tubulogenesis when treated with HGF; thus HGF is func-
tions as a molecular "switch" from tubule formation to
cyst [15]. We showed that p21 is in fact induced by HGF
treatment in MDCK cells, consistent with data from other
cell lines [39], and consistent with our hypothesis that
p21 mediates the tubulogenic, not the cystic, phenotype.
Other than the genes identified as mutant in PKD (Pkd1
[the wild-type of which induces p21 as described above]
and Pkd2), there is a striking paucity of gene targets in this
common genetic disease. Since we have now shown that
p21 possesses an anti-proliferative, and hence likely anti-
cystic, effect on the cystogenic MDCK cell line, and that
p21 is decreased in human ADPKD, it is possible that the
p21 pathway, including the p21waf1 gene, may be utilized
in future therapy of this disease with or without the addi-
tion of another CDK inhibitor such as roscovitine which
itself increases p21. The finding by other investigators that
inhibition of apoptosis, as would be expected to occur
with increase levels of p21, slows ADPKD disease progres-
sion [38] is another potential benefit of such gene ther-
apy. We foresee the ultimate use of CDK inhibition, either
in embryonic or later life, as a possible PKD preventative
measure.
Conclusion
We have shown that p21, a cyclin kinase inhibitor which
mediates cell cycle progression as well as apoptosis, is
decreased in a rat model as well as in human ADPKD, and
that roscovitine, which has been shown to have a salutary
effect in an animal model of this disease, increases levels
of p21. Validation of a potential pathogenetic model of
Hypothesis: attenuated or dysfunctional p21 contributes to  cyst formation in ADPKD Figure 8
Hypothesis: attenuated or dysfunctional p21 contributes to 
cyst formation in ADPKD. It is likely that "normal" p21 pre-
vents renal tubular epithelial cells (RTE) from assuming a 
proliferative, cystic configuration and thwarts the increased 
apoptosis that is seen with attenuated or maldistributed p21 
which we hypothesize occurs in PKD. Myc and KGF contrib-
ute to cyst formation likely in part through p21 attenuation; 
roscovitine increase p21 leading to its salutary anti-prolifera-
tive effect in RTEs.BMC Nephrology 2007, 8:12 http://www.biomedcentral.com/1471-2369/8/12
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increased cyst formation in ADPKD due to enhanced epi-
thelial proliferation and apoptosis mediated by p21 sug-
gests a mechanism for the salutary effect of roscovitine in
this disease and supports further investigation of p21 as a
target for future therapy of this disease.
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